News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiogen Pharma Licenses RFB4 Antibody from Cancer Research Technology



7/11/2007 3:01:12 PM

London, UK: 11th July 2007; Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has agreed an exclusive worldwide licence with Abiogen Pharma S.p.A. (Italy). The agreement supersedes a previous licence with Abiogen and will enable Abiogen to continue to use the RFB4 antibody, in combination with key technology from the University of Texas Southwestern Medical Center at Dallas, to develop its pipeline therapeutics.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES